Hypertension and the kidney

Seminars in Nephrology

Volumn 25, Issue 4, 2005, Pages 236-245

  Wiederkehr, Michael ^a,c   Toto, Robert ^b   Fenves, Andrew Z ^a   Ram, C Venkata S ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c University of Texas Southwestern Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FOSINOPRIL; HYDRALAZINE; IRBESARTAN; LOSARTAN; MINOXIDIL; NISOLDIPINE; RAMIPRIL;

ALCOHOL ABSTINENCE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIABETES CONTROL; DIABETES MELLITUS; DIET; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EXERCISE; GLOMERULUS FILTRATION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY TUBULE PRESSURE; LIFESTYLE; MEDICAL ASSESSMENT; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEPHROSCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; SODIUM RESTRICTION; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 22544457627     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2005.02.008     Document Type: Article

References (101)

1. D.J. Hyman, V.N. Pavlik Characteristics of patients with uncontrolled hypertension in the United States N Engl J Med 345 2001 479 486
2. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 suppl 2 2003 S29 S40
3. J. Coresh, B.C. Astor, T. Greene Prevalence of chronic kidney disease and decreased kidney function in the adult US population Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
4. G.L. Bakris Maximizing cardio-renal benefits Achieving blood pressure goals J Clin Hypertens 41 1999 141 148
5. M.J. Klag, P.K. Whelton, B.L. Randall Blood pressure and end-stage renal disease in men N Engl J Med 334 1996 13 18
6. National Kidney Foundation K/DOQI Clinical Practice Guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 suppl 1 2004 S65 S223
7. United National Institutes of Health US Renal Data System. USRDS 2003 Annual Data Report 2003 Bethesda Maryland
8. UKPDS Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group BMJ 317 1998 713 720
9. S. Ljungman, J. Wikstrand, M. Hartford Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men Am J Hypertens 9 1996 770 778
10. F.M. Sacks, L.P. Svetkey, W.M. Vollmer Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group N Engl J Med 344 2001 3 10
11. M. Ruiz-Ortega, O. Lorenzo, Y. Suzuki Proinflammatory actions of angiotensins Curr Opin Nephrol Hypertens 10 2001 321 329
12. E.J. Lewis, L.G. Hunsicker, R.P. Bain The effect of angiotensin- converting enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
13. The Hope Trial Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 22:355 2000 253 259
14. L. Hansson, L.H. Lindholm, L. Niskanen Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension The Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
15. R.O. Estacio, B.W. Jeffers, W.R. Hiatt The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 1998 645 652
16. P. Tatti, M. Pahor, R.P. Byington Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 597 603
17. S. Yusuf, H. Gerstein, B. Hoogwerf Ramipril and the development of diabetes JAMA 286 2001 1882 1885
18. V. Kon, A. Fogo, I. Ichikawa Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition Kidney Int 44 1993 545 550
19. H.H. Parving, H. Lehnert, J. Brochner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
20. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
21. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
22. S. Yusuf, P. Sleight, J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
23. J.E. Moller, U. Dahlstrom, O. Gotzsche Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction Results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy Am Heart J 147 2004 494 501
24. C.M. Rembold Losartan was more effective than atenolol for isolated systolic hypertension and left ventricular hypertrophy ACP J Club 138 2003 37
25. F.H. Messerli The LIFE study The straw that should break the camel's back Eur Heart J 24 2003 487 489
26. C.E. Mogensen, S. Neldam, I. Tikkanen Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes The candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 2000 1440 1444
27. P. Jacobsen, S. Andersen, K. Rossing Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy Nephrol Dial Transplant 17 2002 1019 1024
28. P. Jacobsen, S. Andersen, B.R. Jensen Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy J Am Soc Nephrol 14 2003 992 999
29. G.D. Laverman, G. Navis, R.H. Henning Dual renin-angiotensin system blockade at optimal doses for proteinuria Kidney Int 62 2002 1020 1025
30. P. Jacobsen, S. Andersen, K. Rossing Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy Kidney Int 63 2003 1874 1880
31. K. Rossing, P. Jacobsen, L. Pietraszek Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy A randomized double-blind crossover trial Diabetes Care 26 2003 2268 2274
32. A. Chrysostomou, G. Becker Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease N Engl J Med 345 2001 925 926
33. J. Klisic, J. Zhang, V. Nief Albumin regulates the Na+/H+ exchanger 3 in OKP cells J Am Soc Nephrol 14 2003 3008 3016
34. S. Klahr, A.S. Levey, G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med 330 1994 877 884
35. Gissen Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet 349 1997 1857 1863
36. P. Ruggenenti, A. Perna, G. Gherardi Chronic proteinuric nephropathies Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury Am J Kidney Dis 35 2000 1155 1165
37. J.T. Wright Jr, G. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial JAMA 288 2002 2421 2431
38. G. Maschio, D. Alberti, G. Janin Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 1996 939 945
39. P. Ruggenenti, A. Perna, G. Gherardi Renoprotective properties of ACEIs inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 1999 359 364
40. R. Schrier, K. McFann, A. Johnson Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease Results of a seven-year prospective randomized study J Am Soc Nephrol 13 2002 1733 1739
41. M.A. van Dijk, M.H. Breuning, R. Duiser No effect of enalapril on progression in autosomal dominant polycystic kidney disease Nephrol Dial Transplant 18 2003 2314 2320
42. T. Ecder, A.B. Chapman, G.M. Brosnahan Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease Am J Kidney Dis 35 2000 427 432
43. T. Nakamura, C. Ushiyama, N. Shimada Effects of the angiotensin II receptor antagonist candesartan cilexetil on blood pressure and proteinuria in patients with autosomal dominant polycystic kidney disease Nephron 86 2000 385 386
44. J. Luno, V. Barrio, M.A. Goicoechea Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies Kidney Int 62 suppl 82 2002 47 52
45. N. Nakao, A. Yoshimura, H. Morita Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) A randomised controlled trial Lancet 361 2003 117 124
46. P. Rutkowski, L. Tylicki, M. Renke Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis Am J Kidney Dis 43 2004 260 268
47. R. Campbell, F. Sangalli, E. Perticucci Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies Kidney Int 63 2003 1094 1103
48. J.N. Cohn, G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
49. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
50. G.H. Williams, E. Burgess, R.E. Kolloch Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension Am J Cardiol 93 2004 990 996
51. N.B. Shulman, C.E. Ford, W.D. Hall Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension 13 1989 I80 I93
52. United National Institutes of Health US Renal Data System. USRDS 2001 Annual Data Report. 12th Annual Report 2001 National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
53. L.Y. Agodoa, L. Appel, G.L. Bakris Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis A randomized controlled trial JAMA 285 2001 2719 2728
54. C.C. Cowie, F.K. Port, R.A. Wolfe Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes N Engl J Med 321 1989 1074 1079
55. W. McClellan, E. Tuttle, A. Issa Racial differences in the incidence of hypertensive end-stage renal disease are not entirely explained by differences in the prevalence of hypertension Am J Kidney Dis 12 1988 285 290
56. A.A. Lopes, F.K. Port, S.A. James The excess risk of treated end-stage renal disease in blacks in the United States J Am Soc Nephrol 3 1993 1961 1971
57. T.V. Perneger, M.J. Klag, P.K. Whelton Race and socioeconomic status in hypertension and renal disease Curr Opin Nephrol Hypertens 4 1995 235 239
58. W.D. Blythe, F.W. Maddux Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980-1986 Am J Kidney Dis 28 1991 33 37
59. T.V. Perneger, F.J. Nieto, P.K. Whelton A prospective study of blood pressure and serum creatinine. Results from the 'Clue' study and the ARIC study JAMA 269 1993 488 493
60. T.V. Perneger, P.K. Whelton, I.B. Puddey Risk of end-stage renal disease associated with alcohol consumption Am J Epidemiol 150 1999 1275 1281
61. F.L. Brancati, J.C. Whittle, P.K. Whelton The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors JAMA 268 1992 3079 3084
62. M.J. Klag, P.K. Whelton, B.L. Randall End-stage renal disease in African-American and white men. 16-year MRFIT findings JAMA 277 1997 1293 1298
63. B.M. Brenner Hemodynamically mediated glomerular injury and the progressive nature of kidney disease Kidney Int 23 1983 647 655
64. B.M. Brenner, G.M. Chertow Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury Am J Kidney Dis 23 1994 171 175
65. N.R. Powe Early referral in chronic kidney disease An enormous opportunity for prevention Am J Kidney Dis 41 2003 505 507
66. N.R. Powe, M.E. Tarver-Carr, M.S. Eberhardt Receipt of renal replacement therapy in the United States A population-based study of sociodemographic disparities from the Second National Health and Nutrition Examination Survey (NHANES II) Am J Kidney Dis 42 2003 249 255
67. M.E. Tarver-Carr, N.R. Powe, M.S. Eberhardt Excess risk of chronic kidney disease among African-American versus white subjects in the United States A population-based study of potential explanatory factors J Am Soc Nephrol 13 2002 2363 2370
68. P. Muntner, J. Coresh, J.C. Smith Plasma lipids and risk of developing renal dysfunction The atherosclerosis risk in communities study Kidney Int 58 2000 293 301
69. P. Muntner, J. He, L. Hamm Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States J Am Soc Nephrol 13 2002 745 753
70. P. Muntner, E. Garrett, M.J. Klag Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age Stroke 33 2002 1209 1213
71. P. Muntner, L.L. Hamm, J.W. Kusek The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease Ann Intern Med 140 2004 9 17
72. J.H. Young, M.J. Klag, P. Muntner Blood pressure and decline in kidney function Findings from the Systolic Hypertension in the Elderly Program (SHEP) J Am Soc Nephrol 13 2002 2776 2782
73. H.M. Perry Jr, J.P. Miller, J.R. Fornoff Early predictors of 15-year end-stage renal disease in hypertensive patients Hypertension 25 1995 587 594
74. C. Burton, K.P. Harris The role of proteinuria in the progression of chronic renal failure Am J Kidney Dis 27 1996 765 775
75. T.H. Jafar, P.C. Stark, C.H. Schmid Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis Ann Intern Med 139 2003 244 252
76. T.H. Jafar, C.H. Schmid, M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
77. R.D. Toto Hypertensive nephrosclerosis. Nephrology forum Kidney Int 64 2003 2331 2341
78. T.H. Jafar, P.C. Stark, C.H. Schmid Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease Kidney Int 60 2001 1131 1140
79. J.T.J. Wright, J.W. Kusek, R.D. Toto Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study Control Clin Trials 17 1996 3S 16S
80. A. Fogo, J.A. Breyer, M.C. Smith AASK Pilot Study Investigators Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans A report from the African American Study of Kidney Disease (AASK) Trial Kidney Int 51 1997 244 252
81. M. Regalado, S. Yang, D.E. Wesson Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension Am J Kidney Dis 35 2000 687 694
82. E. Ritz, H. Ogata, S.R. Orth Smoking A factor promoting onset and progression of diabetic nephropathy Diabet Med 26 2000 54 63
83. J.F. Mann, H.C. Gerstein, J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril The HOPE randomized trial Ann Intern Med 134 2001 629 636
84. C. Gouva, P. Nikolopoulos, J.P. Ioannidis Treating anemia early in renal failure patients slows the decline of renal function A randomized controlled trial Kidney Int 66 2004 753 760
85. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel IIi guidelines Circulation 110 2004 227 239
86. H.S. Mackenzie, M.W. Taal, V.A. Luycks Adaptation to nephron loss B.M. Brenner The Kidney 6th ed. 2000 Saunders Philadelphia 1901 1942
87. UKPDS Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published erratum appears in BMJ 318:29, 1999] BMJ 317 1998 703 713
88. T. Hannedouche, P. Landais, B. Goldfarb Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure BMJ 309 1994 833 837
89. G.R. Sheinfeld, G.L. Bakris Benefits of combination angiotensin- converting enzyme inhibitor and calcium antagonist therapy for diabetic patients Am J Hypertens 12 1999 80S 85S
90. G.L. Bakris, M. Siomos, D. Richardson VAL-K Study Group ACE inhibition or angiotensin receptor blockade Impact on potassium in renal failure Kidney Int 58 2000 2084 2092
91. B.F. Palmer Renal dysfunction complicating the treatment of hypertension N Engl J Med 347 2002 1256 1261
92. G.L. Bakris, M.R. Weir Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine Is this a cause for concern? Arch Intern Med 160 2000 685 693
93. A.J. Apperloo, D. de Zeeuw, P.E. de Jong A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function Kidney Int 51 1997 793 797
94. L. Perez-Oller, R. Torra, C. Badenas Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease Am J Kidney Dis 34 1999 273 278
95. United National Institutes of Health US Renal Data System. USRDS 2002 Annual Data Report 2003 Bethesda Maryland
96. M.P. Horl, W.H. Horl Hemodialysis-associated hypertension Pathophysiology and therapy Am J Kidney Dis 39 2002 227 244
97. R.N. Foley, P.S. Parfrey, J.D. Harnett Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease Kidney Int 49 1996 1379 1385
98. R. Agarwal, A.R. Nissenson, D. Batlle Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States Am J Med 115 2003 291 297
99. A.E. Lazar, M.C. Smith, M. Rahman Blood pressure measurement in hemodialysis patients Semin Dial 17 2004 250 254
100. J.K. Leypoldt, A.K. Cheung, J.A. Delmez Relationship between volume status and blood pressure during chronic hemodialysis Kidney Int 61 2002 266 275
101. M.P. Horl, W.H. Horl Drug therapy for hypertension in hemodialysis patients Semin Dial 17 2004 288 294